These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23284936)

  • 1. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
    Benkert TF; Dietz L; Hartmann EM; Leich E; Rosenwald A; Serfling E; Buttmann M; Berberich-Siebelt F
    PLoS One; 2012; 7(12):e52208. PubMed ID: 23284936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
    Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
    PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
    Börnsen L; Christensen JR; Ratzer R; Oturai AB; Sørensen PS; Søndergaard HB; Sellebjerg F
    PLoS One; 2012; 7(11):e47578. PubMed ID: 23226199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.
    Sottini A; Capra R; Zanotti C; Chiarini M; Serana F; Ricotta D; Caimi L; Imberti L
    PLoS One; 2012; 7(4):e34493. PubMed ID: 22496817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
    Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
    Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-126: a novel route for natalizumab action?
    Meira M; Sievers C; Hoffmann F; Derfuss T; Kuhle J; Kappos L; Lindberg RL
    Mult Scler; 2014 Sep; 20(10):1363-70. PubMed ID: 24598267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.
    Wüthrich C; Popescu BF; Gheuens S; Marvi M; Ziman R; Denq SP; Tham M; Norton E; Parisi JE; Dang X; Lucchinetti CF; Koralnik IJ
    J Neuropathol Exp Neurol; 2013 Nov; 72(11):1043-51. PubMed ID: 24128680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R; Jelčić I; Schippling S; Martin R; Sospedra M
    Eur J Immunol; 2012 Mar; 42(3):790-8. PubMed ID: 22144343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B; Kappos L
    Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
    Puñet-Ortiz J; Hervás-García JV; Teniente-Serra A; Cano-Orgaz A; Mansilla MJ; Quirant-Sánchez B; Navarro-Barriuso J; Fernández-Sanmartín MA; Presas-Rodríguez S; Ramo-Tello C; Martínez-Cáceres EM
    Cytometry B Clin Cytom; 2018 Mar; 94(2):327-333. PubMed ID: 28378895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Natalizumab: an antibody targeting α4-integrin].
    Nakahara J
    Brain Nerve; 2014 Oct; 66(10):1149-58. PubMed ID: 25296869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.
    Kivisäkk P; Healy BC; Viglietta V; Quintana FJ; Hootstein MA; Weiner HL; Khoury SJ
    Neurology; 2009 Jun; 72(22):1922-30. PubMed ID: 19487650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.
    Bühler U; Fleischer V; Luessi F; Rezk A; Belikan P; Graetz C; Gollan R; Wolf C; Lutz J; Bar-Or A; Siffrin V; Zipp F
    Mult Scler; 2017 Apr; 23(4):567-576. PubMed ID: 27436357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
    PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab: Perspectives from the Bench to Bedside.
    Shirani A; Stüve O
    Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29500304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Natalizumab in the treatment of multiple sclerosis].
    Horga A; Horga de la Parte JF
    Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.